

TORCILIN

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for TORCILIN (Cilnidipine Tablets IP 5 mg, 10 mg and 20 mg.)
[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: Cilnidipine is a dihydropyridine calcium channel blocker that inhibits L- and N-type calcium channels. It primarily relaxes vascular smooth muscle, reducing blood pressure. The L-type blockade causes vasodilation, while N-type blockade suppresses norepinephrine release, reducing sympathetic activity. This dual action helps manage hypertension effectively.

INDICATIONS: It is indicated for the treatment of mild to moderate hypertension.

DOSAGE AND ADMINISTRATION: The usual dose of cilnidipine is 5 to 10 mg once daily; if necessary, dosage may be increased to 20 mg once daily. TORCILIN Tablets can be administered regardless of meal. The tablet should be swallowed whole with water. Or, as directed by physician.

CONTRAINDICATION: Hypersensitivity to the active substance, Cilnidipine or to any of the excipients, Cardiogenic shock, Severe aortic stenosis, Recent history of unstable angina or acute myocardial infarction, heart failure, and hypotension.

WARNINGS & PRECAUTIONS: *Cardiovascular Disorders:* Cilnidipine should be used with caution in patients with hypotension, heart failure, and poor cardiac reserve. Cilnidipine should be discontinued immediately in patients who feel chest pain following the administration of the drug. *Abrupt Cessation of Therapy:* In case of angina, cilnidipine should not be discontinued abruptly to avoid withdrawal symptoms. *Grapefruit Juice:* Grapefruit juice may intensify the effect of cilnidipine. Thus, avoid drinking grapefruit juice as much as possible while on cilnidipine therapy. *Laboratory Test:* Cilnidipine therapy may interfere with the results of vanillyl mandelic acid test which is used to detect tumours such as pheochromocytoma and neuroblastoma. Therefore, cilnidipine should be avoided for 72 hours before sample collection, but the patient should be monitored intensively in a clinical setting.

DRUG INTERACTIONS: *Antipsychotic Drugs:* Co-administration of antipsychotic drugs with cilnidipine may result in low blood pressure. Thus, caution should be exercised while concomitant use of these drugs with cilnidipine. *Antidiabetic Drugs:* Co-administration of cilnidipine with antidiabetic drugs may result in changes in glucose levels, thus, monitoring of blood glucose levels may be required. *Other Drugs:* Antiepileptic drugs (such as phenytoin and carbamazepine), rifampin, quinidine, erythromycin, other anti-hypertensive drugs, and aldesleukin should also be used with caution along with cilnidipine.

ADVERSE REACTIONS: Edema (face, limb, etc.), facial flush, thickening of gums, heat sensation, lethargy, generalized fatigue, frequent urination, impotence, liver dysfunction, jaundice, thrombocytopenia (nose/gum bleeding), allergic reaction, *Gastrointestinal:* Nausea, vomiting, anorexia, stomachache, gastrointestinal reflux disease (GERD). *Eye:* Transient blindness, eye pain. *Musculoskeletal:* Muscle ache, tremors. *Cardiovascular System:* Hypotension, palpitations, ischemic chest pain. *Central Nervous System:* Dizziness, headache, depression, cerebral ischemia. *Dermatological:* Rashes, itching, photosensitivity.

MARKETED BY:

TORRENT
PHARMA

TORRENT PHARMACEUTICALS LTD.

IN/TORCILIN 5 mg,10 mg and 20 mg/Feb-2026/03/ABPI

(Additional information is available on request)